Image-guided radiation plus liver procedures for non-surgical liver cancer
Part of Cancer, Digestive system clinical trials.
This trial studies a combination approach—special, image-guided radiation and liver procedures—for liver cancer patients who cannot have surgery. It may help shrink tumors while protecting liver function by using planned, targeted treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (hepatocellular carcinoma) confirmed on a scan (CT/MRI) or by biopsy
- You are age 18 or older
- Your daily functioning is good (ECOG score 0 to 2)
- Your liver is working fairly well (Child-Pugh A5 to B8, but not worse)
- The tumor area fits the plan: one lesion up to 5 cm or up to 3 lesions total
- Your tumor(s) can be treated with both the liver procedure and the image-guided radiation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
This Phase I study tests a specific radiation approach (vGRID SBRT) for hepatocellular carcinoma (and some mixed types) that is advanced and cannot be cured with surgery or transplant. It aims to control tumors while staying within safety limits for the liver and nearby organs.
This trial tests a combination of radiation therapy, an immunotherapy drug called camrelizumab, and a targeted therapy pill called apatinib for people with advanced liver cancer that has spread to the main blood vessel of the liver. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
This study tests a new combination for liver cancer that has not responded to one earlier treatment. It uses a focused type of radiation (SBRT) plus an immunotherapy drug called QL1706 (a medicine that helps your immune system attack cancer). The goal is to see if this combination can control the cancer better.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial tests combining an immunotherapy drug (sintilimab) with targeted radiation therapy before surgery to shrink liver tumors and improve the chances of successful removal. It is designed for people with resectable liver cancer who have not yet had systemic treatment.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.